BioPharma Credit (LSE:BPCR) Stock Based Compensation: $0.0 Mil (TTM As of Dec. 2025)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
52 GF Score
Price $0.96
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Stock Based Compensation?

BioPharma Credit LSE:BPCR 52 Stock Based Compensation is $0.0 Mil as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

BioPharma Credit's Stock Based Compensation for the six months ended in Dec. 2025 was $0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

BioPharma Credit Stock Based Compensation Related Terms

BioPharma Credit Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Stock Based Compensation Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:BPCR
52GF Score
BioPharma Credit PLC LSE:BPCR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Stock Based Compensation of $0.0 Mil mean?
BioPharma Credit (LSE:BPCR) has a Stock Based Compensation of $0.0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioPharma Credit and its competitors.
Is BioPharma Credit's Stock Based Compensation too high?
BioPharma Credit's current Stock Based Compensation is $0.0 Mil. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Stock Based Compensation compare to BLK and BX?
BioPharma Credit's Stock Based Compensation of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for an Asset Management company?
A good Stock Based Compensation depends on the Asset Management industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for BioPharma Credit and its competitors. BioPharma Credit's current Stock Based Compensation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading right at its estimated fair value. The current Stock Based Compensation is $0.0 Mil. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Stock Based Compensation is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 0% below its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Stock Based Compensation: $0.0 Mil
  • GF Value™: $0.96 vs. price of $0.96 (0% below fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score

Get the complete analysis for LSE:BPCR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.96
GF Value